Loading clinical trials...

Management of Nausea and Vomiting Chemotherapy-induced in Normandy | Clinical Trials | Clareo Health

COMPLETED

Management of Nausea and Vomiting Chemotherapy-induced in Normandy

NCT01440465•Centre Francois Baclesse

Summary

The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged over 18 years
•With solid tumors or hematologic in first line chemotherapy, administered intravenously,
•Able to understand the meaning of the questions
•Having given their written consent to participate in the survey.

Exclusion Criteria

•This does not concern patients who:
•Do not give their consent for participation
•Do not speak French
•Suffer from cognitive deficits
•Are under therapy
•Must receive a combination of radio-chemotherapy
•Present an occlusive syndrome
•Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
•Have been previously treated with chemotherapy
•Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors
+1 more criteria

Locations (6)

Centre de la Baie

Avranches, France

Centre hospitalier

Bayeux, France

Centre Maurice Tubiana

Caen, France

Centre François Baclesse

Caen, France

Centre hospitalier public du cotentin

Cherbourg-Octeville, France

Centre Jacques Monod

Flers, France

Key Dates

Start Date

July 1, 2011

Primary Completion Date

January 1, 2013

Completion Date

February 1, 2013

Last Updated

December 17, 2025

Enrollment

300

ACTUAL participants

Conditions

CancerNauseaVomiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGEARLY_PHASE1

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398

Skin CancerKidney Transplant Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Management of Nausea and Vomiting Chemotherapy-induced in Normandy

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Early Detection of Liver Cancer by QUS